15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Novavax Inc, 4 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $9.00 to $19.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $14.00 sits 37% above the current $10.19. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy467%
Hold117%
Sell117%
Strong Sell00%
Based on 6 analysts giving stock ratings to Novavax Inc.
As of Sep, 4 of 6 firms rate NVAX a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
NVAX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.47 – $0.31 · 8 analysts · -200% YoY
Next period, 8 analysts expect Novavax Inc to earn $-0.11 a share (range $-0.47 – $0.31), versus $0.11 a year earlier. Full-year consensus is $-0.63, growing to $-0.22 the year after.
REVENUE · NEXT QUARTER
$92.9M
Range $33.1M – $154.0M · 8 analysts · -37% YoY
Revenue is expected to reach $92.9M (range $33.1M – $154.0M), -36.8% year-over-year. Full-year consensus is $372.9M, rising to $266.2M next year.
Top analysts covering Novavax Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVAX.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$18.00+76.6% to target
Overall win rate
50%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #75
Sell
$6.00-41.1% to target
Overall win rate
51%
+ Follow
#3
Roger Song
Jefferies · Rank #101
Buy
$25.00+145.3% to target
Overall win rate
43%
+ Follow
#4
Sean Lee
HC Wainwright & Co. · Rank #232
Buy
$10.00-1.9% to target
Overall win rate
43%
+ Follow
#5
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #233
Buy
$18.00+76.6% to target
Overall win rate
36%
+ Follow
NVAX stock forecast FAQ
What is NVAX's average 12-month price target?+
The 2 analysts with a live target average $14.00 for Novavax Inc over the next 12 months, ranging from a $19.00 high to a $9.00 low.
Is NVAX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for NVAX?+
The Street-high target is $19.00 (BTIG), and the Street-low is $9.00 (TD Cowen). The average of all 2 active targets is $14.00.
How many Wall Street analysts cover NVAX?+
6 analysts have an active rating on Novavax Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NVAX?+
Among analysts who currently cover NVAX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $18.00 target.
What is Novavax Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.47 – $0.31) across 8 analysts. Full-year EPS is projected at $-0.63, rising to $-0.22 the following year.
How much revenue is Novavax Inc expected to report next quarter?+
Consensus revenue is $92.9M (range $33.1M – $154.0M). Full-year revenue is projected at $372.9M, growing to $266.2M next year.
Have analysts been upgrading or downgrading NVAX lately?+
As of Sep, 4 of 6 firms rate NVAX a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
